Melperon Stada

Melperone, the active ingredient in Melperon Stada, is a butyrophenone antipsychotic presented as a tablet for oral use. It is indicated for the management of schizophrenia and acute psychotic episodes in adult patients, acting on dopaminergic and serotonergic pathways to reduce psychotic symptoms.

GNH USA supplies Melperon Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and reliable, with distribution channels that meet EU regulatory standards and ensure product integrity throughout the supply chain across the supply chain.

Melperone is a butyrophenone antipsychotic used to manage psychotic disorders by modulating dopamine and serotonin activity. - Schizophrenia: helps reduce hallucinations, delusions and thought disorder in adult patients. - Acute psychotic episodes: alleviates sudden onset of psychotic symptoms such as agitation and paranoia. - Psychotic symptoms in other mental health conditions: provides symptom control when psychosis occurs secondary to other disorders.

Melperone may be associated with a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Sedation: feeling of drowsiness or reduced alertness. - Orthostatic hypotension: dizziness or light‑headedness upon standing. - Dry mouth: reduced salivation leading to discomfort. - Constipation: decreased bowel movements causing abdominal discomfort. - Weight gain: increase in body weight over treatment course. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Tardive dyskinesia: involuntary, repetitive movements, especially of the face. - Neuroleptic malignant syndrome: fever, muscle rigidity, autonomic instability. - Agranulocytosis: marked decrease in white blood cells, increasing infection risk. - Seizures: rare occurrence of convulsive episodes, requiring immediate medical attention.

When prescribing melperone, several safety considerations should be observed to minimize risk. - Dose adjustment: consider renal or hepatic impairment before initiating therapy. - Monitor: regular assessment for extrapyramidal symptoms and metabolic changes. - Avoid: use in patients with known hypersensitivity to melperone or related compounds. - Caution: may impair psychomotor performance; advise patients not to operate machinery or drive until they know how the drug affects them. - Pregnancy: safety not established; use only if potential benefit justifies potential risk to the fetus. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Melperone can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP2D6 inhibitors: may increase melperone plasma concentrations, raising toxicity risk. - Other antipsychotics: additive central nervous system depression and heightened extrapyramidal effects. - QT‑prolonging drugs: combined use may increase the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers: may reduce melperone efficacy by enhancing metabolism. - Anticholinergic agents: may mask anticholinergic side effects of melperone. - Alcohol: can potentiate sedation and dizziness, requiring caution.